Table of contents

01 - Pre-Meeting Briefing prepared by NICE

02 – Full preceding guidance – Immunosuppressant therapy for renal transplantation in adults [TA85]

04 –  Comments on the Assessment Report – Astellas Pharma

05 - Comments on the Assessment Report – Novartis

06 –Comments on the economic model - Novartis 

07 – Additional analyses – Novartis

08 – Corrections to the economic model – Novartis 

09 Consultee comments on the assessment report – Sandoz

10 Comments on the Assessment Report – –Sanofi Ltd

11 Comments on the Assessment Report – –Teva UK

12 Comments on the Assessment Report – – The Efficiency and Safety of prescribing in Transplantation (ESPRIT)

13 Consultee comments on the assessment report –British Transplantation Society

14 Comments on the Assessment Report – NHS England

15 Comments on the Assessment Report – Health Improvement Scotland

16- Clinical expert comments on the Assessment Report - Watson 

17 – Response to comments on the Assessment Report prepared by PenTAG 

18 – Assessment Report addendum by PenTAG

19 – Response to Novartis’ comments on the economic model

20 – Assessment Report errata  by PenTAG

21 – Assessment Report updated results section by PenTAG

22 – Assessment Report errata:  Appendix 7  by PenTAG

23 – Executive summary of technology submission – Astellas Pharma

24 – Information about discounted prices from Astellas Pharma 

25 - Executive summary of technology submission – Bristol-Myers Squibb

26 – Executive summary of technology submission – Novartis

27 – Executive summary of technology submission – Sandoz

28 – Executive summary of technology submission –Teva UK

29 – Consultee submission – The Efficiency and Safety of prescribing in Transplantation (ESPRIT) Group

30 – Consultee submission – British Transplantation Society

31 – Consultee submission – Kidney Research UK

32 – Clinical expert statement – Wilson